866-997-4948(US-Canada Toll Free)

Skeletal Disease Drug Development Pipeline Review, 2017

Published By :

GBI Research

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 176 Pages

Skeletal Disease Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the skeletal disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA).

OA is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Postmenopausal osteoporosis is the most common subtype of osteoporosis, and affects many women after menopause. Signs and symptoms of osteoporosis include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and other osteoporosis medications.

The size of these pipelines ranges from 13 products in postmenopausal osteoporosis to 116 in OA. The predominant targets within OA are prostaglandin G/H synthases 1 and 2, although a wide range of targets, including extracellular matrix-organizing proteins and interleukins, are being studied. Likewise, within both osteoporosis and the post-menopausal subtype, a broad range of molecular targets are being studied. The targets being most frequently studied are the parathyroid hormone receptor, tumor necrosis factor ligand superfamily member 11 and sclerostin.

Scope

- Which companies are the most active within the pipeline for osteoporosis and OA therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of osteoporosis and OA therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 5
List of Figures 9
Introduction 10
Skeletal Disease Report Coverage 10
Osteoarthritis - Overview 10
Osteoporosis - Overview 10
Post Menopausal Osteoporosis - Overview 10
Therapeutics Development 11
Osteoarthritis 11
Osteoporosis 21
Post Menopausal Osteoporosis 31
Therapeutics Assessment 34
Osteoarthritis 34
Osteoporosis 44
Post Menopausal Osteoporosis 54
Companies Involved in Therapeutics Development 62
Osteoarthritis 62
Osteoporosis 96
Post Menopausal Osteoporosis 124
Dormant Projects 129
Osteoarthritis 129
Osteoporosis 133
Post Menopausal Osteoporosis 138
Discontinued Products 139
Osteoarthritis 139
Osteoporosis 140
Post Menopausal Osteoporosis 141
Product Development Milestones 142
Osteoarthritis 142
Osteoporosis 154
Post Menopausal Osteoporosis 164
Appendix 175
Methodology 175
Coverage 175
Secondary Research 175
Primary Research 175
Expert Panel Validation 175
Contact Us 175
Disclaimer 176

List of Tables
Number of Products under Development for Osteoarthritis 11
Number of Products under Development by Companies, Osteoarthritis 13
Number of Products under Development by Universities/Institutes, Osteoarthritis 15
Products under Development by Companies, Osteoarthritis 16
Products under Development by Universities/Institutes, Osteoarthritis 20
Number of Products under Development for Osteoporosis 21
Number of Products under Development by Companies, Osteoporosis 23
Number of Products under Development by Universities/Institutes, Osteoporosis 25
Products under Development by Companies, Osteoporosis 26
Products under Development by Universities/Institutes, Osteoporosis 30
Number of Products under Development for Post Menopausal Osteoporosis 31
Number of Products under Development by Companies, Post Menopausal Osteoporosis 32
Products under Development by Companies, Post Menopausal Osteoporosis 33
Number of Products by Stage and Target, Osteoarthritis 35
Number of Products by Stage and Mechanism of Action, Osteoarthritis 38
Number of Products by Stage and Route of Administration, Osteoarthritis 41
Number of Products by Stage and Molecule Type, Osteoarthritis 43
Number of Products by Stage and Target, Osteoporosis 45
Number of Products by Stage and Mechanism of Action, Osteoporosis 48
Number of Products by Stage and Route of Administration, Osteoporosis 51
Number of Products by Stage and Molecule Type, Osteoporosis 53
Number of Products by Stage and Target, Post Menopausal Osteoporosis 55
Number of Products by Stage and Mechanism of Action, Post Menopausal Osteoporosis 57
Number of Products by Stage and Route of Administration, Post Menopausal Osteoporosis 59
Number of Products by Stage and Molecule Type, Post Menopausal Osteoporosis 61
Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl 62
Osteoarthritis - Pipeline by AbbVie Inc 62
Osteoarthritis - Pipeline by Abiogen Pharma SpA 63
Osteoarthritis - Pipeline by Ablynx NV 63
Osteoarthritis - Pipeline by Achelios Therapeutics Inc 64
Osteoarthritis - Pipeline by Addex Therapeutics Ltd 64
Osteoarthritis - Pipeline by Amgen Inc 65
Osteoarthritis - Pipeline by Amura Holdings Ltd 65
Osteoarthritis - Pipeline by Arcarios BV 66
Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp 66
Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc 67
Osteoarthritis - Pipeline by Astellas Pharma Inc 67
Osteoarthritis - Pipeline by Biopharm GmbH 68
Osteoarthritis - Pipeline by Bone Therapeutics SA 68
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd 69
Osteoarthritis - Pipeline by Cardax Inc 69
Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc 70
Osteoarthritis - Pipeline by Cipla Ltd 70
Osteoarthritis - Pipeline by Corestem Inc 71
Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd 71
Osteoarthritis - Pipeline by Evgen Pharma Plc 72
Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd 72
Osteoarthritis - Pipeline by Galapagos NV 73
Osteoarthritis - Pipeline by Gemphire Therapeutics Inc 73
Osteoarthritis - Pipeline by GeneFrontier Corp 74
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH 74
Osteoarthritis - Pipeline by GlaxoSmithKline Plc 75
Osteoarthritis - Pipeline by HSRx Group 75
Osteoarthritis - Pipeline by InKemia IUCT Group SA 76
Osteoarthritis - Pipeline by International Stem Cell Corp 76
Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd 77
Osteoarthritis - Pipeline by Jenrin Discovery Inc 77
Osteoarthritis - Pipeline by K-Stemcell Co Ltd 78
Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd 78
Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc 79
Osteoarthritis - Pipeline by LG Chem, Ltd. 79
Osteoarthritis - Pipeline by Marina Biotech Inc 80
Osteoarthritis - Pipeline by Medivir AB 80
Osteoarthritis - Pipeline by Merck KGaA 81
Osteoarthritis - Pipeline by Mesoblast Ltd 81
Osteoarthritis - Pipeline by Mor Research Application Ltd 82
Osteoarthritis - Pipeline by NicOx SA 82
Osteoarthritis - Pipeline by Nordic Bioscience A/S 83
Osteoarthritis - Pipeline by Novartis AG 83
Osteoarthritis - Pipeline by NovelMed Therapeutics Inc 84
Osteoarthritis - Pipeline by Omeros Corp 84
Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd 85
Osteoarthritis - Pipeline by OrthoCyte Corp 85
Osteoarthritis - Pipeline by Osteologix Holdings Plc 86
Osteoarthritis - Pipeline by Pfizer Inc 86
Osteoarthritis - Pipeline by Pharmalink AB 87
Osteoarthritis - Pipeline by Philogen SpA 87
Osteoarthritis - Pipeline by PhytoHealth Corp 88
Osteoarthritis - Pipeline by PLx Pharma Inc 88
Osteoarthritis - Pipeline by ProteoThera Inc 89
Osteoarthritis - Pipeline by Regeneus Ltd 89
Osteoarthritis - Pipeline by Regulaxis SAS 90
Osteoarthritis - Pipeline by Rottapharm Biotech Srl 90
Osteoarthritis - Pipeline by Samumed LLC 91
Osteoarthritis - Pipeline by Seikagaku Corp 91
Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd 92
Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd 92
Osteoarthritis - Pipeline by TissueGene Inc 93
Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd 93
Osteoarthritis - Pipeline by Yuhan Corp 94
Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd 94
Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc 95
Osteoporosis - Pipeline by Addex Therapeutics Ltd 96
Osteoporosis - Pipeline by Alize Pharma SAS 96
Osteoporosis - Pipeline by Alvogen Korea Co Ltd 97
Osteoporosis - Pipeline by Amgen Inc 97
Osteoporosis - Pipeline by Amura Holdings Ltd 98
Osteoporosis - Pipeline by BiologicsMD Inc 98
Osteoporosis - Pipeline by Bone Biologics Corp 99
Osteoporosis - Pipeline by Bristol-Myers Squibb Company 99
Osteoporosis - Pipeline by Cellmid Ltd 100
Osteoporosis - Pipeline by ChoDang Pharm Co Ltd 100
Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd 101
Osteoporosis - Pipeline by Corium International Inc 101
Osteoporosis - Pipeline by Critical Pharmaceuticals Ltd 102
Osteoporosis - Pipeline by Daiichi Sankyo Company Ltd 102
Osteoporosis - Pipeline by ElexoPharm GmbH 103
Osteoporosis - Pipeline by EndoCeutics Inc 103
Osteoporosis - Pipeline by Entera Bio Ltd 104
Osteoporosis - Pipeline by Enteris BioPharma Inc 104
Osteoporosis - Pipeline by Enzo Biochem Inc 105
Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd 105
Osteoporosis - Pipeline by Gador SA 106
Osteoporosis - Pipeline by GL Pharm Tech Corp 106
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Ltd 107
Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd 107
Osteoporosis - Pipeline by Haoma Medica Ltd 108
Osteoporosis - Pipeline by Immunovo BV 108
Osteoporosis - Pipeline by Immunwork Inc 109
Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd 109
Osteoporosis - Pipeline by Ipsen SA 110
Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd 110
Osteoporosis - Pipeline by Lead Discovery Center GmbH 111
Osteoporosis - Pipeline by Ligand Pharmaceuticals Inc 111
Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd 112
Osteoporosis - Pipeline by Lupin Ltd 112
Osteoporosis - Pipeline by Merck & Co Inc 113
Osteoporosis - Pipeline by Mereo Biopharma Group Plc 113
Osteoporosis - Pipeline by NIBEC 114
Osteoporosis - Pipeline by Omeros Corp 114
Osteoporosis - Pipeline by Oncobiologics Inc 115
Osteoporosis - Pipeline by Osteologix Holdings Plc 115
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy 116
Osteoporosis - Pipeline by Pfenex Inc 116
Osteoporosis - Pipeline by PhytoHealth Corp 117
Osteoporosis - Pipeline by R Pharm 117
Osteoporosis - Pipeline by Ribomic Inc 118
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 118
Osteoporosis - Pipeline by Shin Poong PharmCo Ltd 119
Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd 119
Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd 120
Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co Ltd 120
Osteoporosis - Pipeline by Terpenoid Therapeutics Inc 121
Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd 121
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd 122
Osteoporosis - Pipeline by Viking Therapeutics Inc 122
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo 123
Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd 123
Osteoporosis - Pipeline by Zydus Cadila Healthcare Ltd 124
Post Menopausal Osteoporosis - Pipeline by Amgen Inc 124
Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc 125
Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd 125
Post Menopausal Osteoporosis - Pipeline by Ipsen SA 126
Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals Inc 126
Post Menopausal Osteoporosis - Pipeline by Lupin Ltd 127
Post Menopausal Osteoporosis - Pipeline by NIBEC 127
Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc 128
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy 128
Osteoarthritis - Dormant Projects 129
Osteoporosis - Dormant Projects 133
Post Menopausal Osteoporosis - Dormant Projects 138
Osteoarthritis - Discontinued Products 139
Osteoporosis - Discontinued Products 140
Post Menopausal Osteoporosis - Discontinued Products 141

List of Figures
Number of Products under Development for Osteoarthritis 11
Number of Products under Development by Companies, Osteoarthritis 12
Number of Products under Development by Universities/Institutes, Osteoarthritis 15
Number of Products under Development for Osteoporosis 21
Number of Products under Development by Companies, Osteoporosis 22
Number of Products under Development by Universities/Institutes, Osteoporosis 25
Number of Products under Development for Post Menopausal Osteoporosis 31
Number of Products under Development by Companies, Post Menopausal Osteoporosis 32
Number of Products by Top 10 Targets, Osteoarthritis 34
Number of Products by Stage and Top 10 Targets, Osteoarthritis 34
Number of Products by Top 10 Mechanism of Actions, Osteoarthritis 37
Number of Products by Stage and Top 10 Mechanism of Actions, Osteoarthritis 37
Number of Products by Routes of Administration, Osteoarthritis 40
Number of Products by Stage and Routes of Administration, Osteoarthritis 40
Number of Products by Top 10 Molecule Types, Osteoarthritis 42
Number of Products by Stage and Top 10 Molecule Types, Osteoarthritis 42
Number of Products by Top 10 Targets, Osteoporosis 44
Number of Products by Stage and Top 10 Targets, Osteoporosis 44
Number of Products by Top 10 Mechanism of Actions, Osteoporosis 47
Number of Products by Stage and Top 10 Mechanism of Actions, Osteoporosis 47
Number of Products by Top 10 Routes of Administration, Osteoporosis 50
Number of Products by Stage and Top 10 Routes of Administration, Osteoporosis 50
Number of Products by Top 10 Molecule Types, Osteoporosis 52
Number of Products by Stage and Top 10 Molecule Types, Osteoporosis 52
Number of Products by Targets, Post Menopausal Osteoporosis 54
Number of Products by Stage and Targets, Post Menopausal Osteoporosis 54
Number of Products by Mechanism of Actions, Post Menopausal Osteoporosis 56
Number of Products by Stage and Mechanism of Actions, Post Menopausal Osteoporosis 56
Number of Products by Routes of Administration, Post Menopausal Osteoporosis 58
Number of Products by Stage and Routes of Administration, Post Menopausal Osteoporosis 58
Number of Products by Molecule Types, Post Menopausal Osteoporosis 60
Number of Products by Stage and Molecule Types, Post Menopausal Osteoporosis 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *